

Dyspnea and Hyperinflation in Chronic Obstructive Pulmonary Disease: Impact on Physical Activity

Nathaniel Marchetti, DO; and Alan Kaplan, MD

Introduction

Dyspnea, the sensation of difficult or labored breathing, is the most common symptom in chronic obstructive pulmonary disease (COPD) and the primary symptom that limits physical activity in more advanced disease.¹ According to the American Thoracic Society, dyspnea may be measured according to 3 domains²:

- what breathing feels like for the patient
- how distressed the patient feels when breathing
- how dyspnea affects functional ability, employment, health-related quality of life, or health status.

Several studies have shown that patients find dyspnea and other COPD symptoms most cumbersome in the early morning and at night-time.^{3,4} However, symptoms can often

be underreported by patients.⁵ The impact of COPD symptoms manifests in various aspects of patients' day-to-day lives, perhaps none more significantly than in the context of physical activity. Inability to engage in sustained physical activity is a common feature of COPD, and even in cases of mild COPD, activity restriction can be evident.⁶ An estimated 29% to 44% of patients with COPD report persistent and troublesome activity-related dyspnea, which may occur early in the disease course.^{6,7} While a number of factors are thought to contribute to the reduced physical activity observed in COPD patients, dyspnea has been identified as a primary contributor.⁸ Patients with COPD may enter a downward spiral of dyspnea-induced inactivity, resulting in muscular and aerobic deconditioning (**FIGURE 1**),^{9,10} which, in turn, results in an increased unwillingness to attempt activity in the future.¹¹

As disease severity increases, breathlessness becomes more disabling at lower activity levels. These changes further impact the quality of life of patients, and can lead to anxiety and depression.¹¹

Physical inactivity is often considered to be a major contributor to the progression of COPD,⁶ and is linked to hospitalizations and increased all-cause mortality.¹² There is therefore a need to recognize symptoms early and treat them accordingly.

Nathaniel Marchetti, DO, Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania

Alan Kaplan, MD, Family Physician Airways Group of Canada, Ontario, Canada

DISCLOSURES

Dr. Marchetti has no conflicts of interest.


Dr. Kaplan has been a speaker or an advisory board member for AstraZeneca; Becton, Dickinson and Company; Boehringer Ingelheim, GmbH; GlaxoSmithKline; Johnson & Johnson; Mylan Laboratories Inc.; Paladin Labs Inc.; Pfizer Inc.; Purdue Pharma L.P.; Novartis Pharmaceuticals Corporation; and Trudell Medical International.

Funding for this article was provided by AstraZeneca LP (Wilmington, DE, USA). Medical writing support was provided by Hannah Burke, BSc, of Core (London, UK) and editorial support was provided by Maryam Vahdat, PGDip, of Core (London, UK), which were funded by AstraZeneca LP (Wilmington, DE, USA), in accordance with Good Publication Practice guidelines (Battisti WP et al. *Ann Intern Med*. 2015;163:461–464. doi: 10.7326/M15-0288).

This article is being co-published in *The Journal of Family Practice* and *Cleveland Clinic Journal of Medicine*.
doi: 10.3949/ccjm.85.s1.02

CASE STUDY:

KD, a 64-year-old woman, presented to her primary care physician's office for a routine visit. Upon assessment, KD revealed that she used to enjoy going on walks with her neighbor, but she cannot walk up the hills in her neighborhood anymore without feeling "incredibly breathless." She has become increasingly concerned that she is "having trouble getting a full breath." KD informed her doctor that these symptoms had worsened since her last visit, and so she had stopped going on neighborhood walks. She was diagnosed with COPD 4 years ago, and is currently using a long-acting muscarinic antagonist (LAMA) bronchodilator. KD has a 40 pack-year smoking history, and has previously been advised to stop smoking, but has relapsed several times. She has a medical

FIGURE 1 The dyspnea spiral¹⁰

Abbreviation: ADLs, activities of daily living.

This figure was published in *Principles and Practice of Pulmonary Rehabilitation*, Haas F, Salazar-Schicci J, Axen K. Desensitization to dyspnoea in chronic obstructive pulmonary disease, 241–251, Copyright Elsevier 1993.

history of hypertension and depression, and a notable family history of emphysema, breast cancer, and diabetes.

The relationship between lung hyperinflation and dyspnea in COPD

In COPD, pathologic changes give rise to physiologic abnormalities such as mucus hypersecretion and ciliary dysfunction, gas exchange abnormalities, pulmonary hypertension, and airflow limitation and lung hyperinflation.¹³ Lung hyperinflation, an increase in resting functional residual volume above a normal level, represents a mechanical link between the characteristic expiratory airflow impairment, dyspnea, and physical activity limitation in COPD.¹

The lungs of patients with COPD can be hyperinflated both at rest (static hyperinflation) and/or during exercise (dynamic hyperinflation).¹⁴ Static hyperinflation is caused by a decrease in elasticity of the lung due to emphysema, resulting in decreased lung recoil pressure and a higher resting lung volume.¹⁵ In dynamic hyperinflation (**FIGURE 2**),^{15,16} the lungs operate at progressively higher volumes of air with each breath, approaching total lung capacity (TLC); this is made worse during exertion as the respiratory rate increases, allowing less time for exhalation.¹⁷ As a result, the volume of air taken in on each breath becomes more limited

by higher end-expiratory lung volumes, and the “work” of breathing is increased.¹⁷

Although patients can compensate for several of the negative consequences of hyperinflation (eg, altering the chest wall due to overdistended lungs), such compensatory mechanisms are unable to cope with large increases in ventilation, such as those that occur during exercise.¹ Air trapping, together with ineffectiveness of respiratory muscle function, leads to increased ventilation requirements and dynamic pulmonary hyperinflation, resulting in dyspnea.¹

Patients with COPD describe a sensation of “air hunger,” reporting “unsatisfied” or “unrewarded” inhalation, “shallow breathing,” and a feeling that they “cannot get a deep breath,”¹⁸ whereas, in fact, they are limited in their ability to fully exhale. Verbal descriptors (eg, “air hunger” or “chest tightness”) are important tools in understanding a patient’s experience with dyspnea, and a patient’s choice of descriptor may be related to dyspnea severity, and the level of distress that dyspnea causes a given patient.¹⁹ Air hunger in turn encourages faster breathing, leading to further shortness of breath and more dynamic hyperinflation.^{1,20}


To deflate the lungs of patients with COPD, physiologic, pharmacologic, and possibly surgical interventions are required:

- Controlled breathing techniques (eg, purse-lipped breathing) that encourage slow and deep breathing can correct abnormal chest wall motion, decrease the work of breathing, increase breathing efficiency, and improve the distribution of ventilation to empty the lungs.²¹
- Bronchodilators can help to achieve lung deflation by improving ventilatory mechanics, as shown by increases in inspiratory capacity and vital capacity.²²
- Lung volume reduction surgery can also be considered to treat severe hyperinflation in emphysematous patients⁵; bronchoscopic interventions that lower lung volumes are also in development.²³

The impact of lung hyperinflation and dyspnea on physical activity in COPD

Dynamic hyperinflation can develop early in COPD, when patients generally experience dyspnea only during more intense exertion.^{11,22} However, as COPD progresses and airflow limitation increases, patients begin to experience shortness of breath with minimal effort and, eventually, during activities of daily living (ADLs), or even at rest.^{5,11} It is important that dyspnea, as well as airway obstruction, is considered as a variable that affects mortality in patients with COPD. Categorizing patients with COPD based on dyspnea severity has been shown to be a more effective predictor of mortality than using classifications based on

FIGURE 2 Changes in operational lung volumes shown as ventilation increases in (A) healthy individuals and (B) patients with COPD¹⁶



Abbreviations: COPD, chronic obstructive pulmonary disease; EELV, end-expiratory lung volume; EILV, end-inspiratory lung volume; IC, inspiratory capacity; IRV, inspiratory reserve volume; TLC, total lung capacity; VC, vital capacity; V_T , tidal volume.

Reprinted with permission of the American Thoracic Society. Copyright © 2018 American Thoracic Society. O'Donnell DE, Revill SM, Webb KA, 2001. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 164(5):770–777. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.

percentage of predicted forced expiratory volume in 1 second (FEV_1) (FIGURE 3).²⁴ Similarly, inspiratory capacity (IC), a surrogate measure of hyperinflation, shows better correlation with exercise endurance time than FEV_1 .²⁶ Resting IC, measured as the IC/TLC ratio (which is approximately 60% in healthy individuals²⁷) has also been identified as an independent risk factor for mortality in patients with COPD²⁸; in their study, Casanova et al examined the predictive capacity of various IC/TLC ratios, ranging from 15% to 40%, and found that an IC/TLC threshold of 25% provided the best power to predict mortality in patients with COPD.²⁸

Dyspnea and hyperinflation are closely interrelated with physical activity limitation,^{16,29,30} and so can be viewed as significant contributors to patient disability. During an acute exacerbation, patients with COPD will experience worsening airway obstruction, dynamic hyperinflation, and dyspnea.³¹ Patients with a greater number of comorbid conditions may also have greater shortness of breath.³² In addition, patients with COPD and hyperinflation perform less physical activity than individuals without hyperinflation, regardless of COPD severity, as assessed using the 2007 Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging (stage I, mild; stage II, moderate; stage III, severe; stage IV, very severe) and BODE (Body-mass index, airflow Obstruction, Dyspnea, and Exercise) index.³³ These patients also exhibit increases in dyspnea perception during commonly per-


formed ADLs, which may limit physical activity and worsen lung hyperinflation.³³ More limited physical activity also contributes to higher dyspnea scores during ADLs.⁸

Furthermore, the ability to perform typical ADLs may be significantly altered or eliminated altogether in patients with COPD.¹¹ Leisure activities are often the first to be dropped by patients, as they generally require greater effort than simpler tasks, and are not critical to daily life.¹¹ Eventually, these activities become progressively more difficult, and most patients with moderate or severe COPD can struggle to complete even the most basic daily activities.¹¹

In addition to the morbidity burden and impact on ADLs, lower levels of physical activity in patients with COPD have also been shown to increase the risk of mortality and exacerbations, and elevate the risk of comorbidities such as heart disease and metabolic disease.³⁴ In light of these observations, improving exercise capacity should be a key goal in COPD management.

Assessment and measurement of dyspnea and hyperinflation

Reducing hyperinflation and dyspnea is essential for improving physical activity endurance and overall physical activity in patients with COPD; therefore, measuring the degree of impairment is important.²² Clinicians should be aware that some patients may have relief of dyspnea due to improvements in hyperinflation, despite relatively mild changes in FEV_1 .³⁵ Lung

FIGURE 3 Five-year survival according to (A) percentage of predicted FEV₁ and (B) dyspnea level²⁴

Abbreviation: FEV₁, forced expiratory volume in 1 second.

(A) Grades determined by 1995 American Thoracic Society staging guideline, which is categorized according to percentage of predicted FEV₁. (B) Grades determined by an adapted version of the Medical Research Council grading system (distinct from the modified Medical Research Council scale, which is used widely and cited in the GOLD report,⁵ in which dyspnea is classified from Grade 0 to Grade 4), developed by Fletcher et al²⁵: Grade I, I get breathless at times other than when doing strenuous exercise; Grade II, I am short of breath when hurrying on the level or walking up a slight hill; Grade III, I have to walk slower than most people on the level and I have to stop after a mile or so (or after 1/4 hour) on the level at my own pace; Grade IV, I have to stop for breath after walking about 100 yards (or after a few minutes) on the level; Grade V, I am too breathless to leave the house, or breathless after undressing.

Reprinted from *Chest*, 121(5), Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD, 1434–1440. Copyright 2002, with permission from Elsevier.

volume measures, including total lung capacity, residual volume and functional residual capacity, are valuable tools in the assessment of lung hyperinflation in COPD, and therefore constitute a key component of pulmonary function testing.³⁶ However, expanded pulmonary function testing may be required for patients with severe dyspnea that does not correspond to spirometric findings, or cases in which diagnosis is uncertain.³⁷

Lung volumes are evaluated primarily by body plethysmography, during which a patient sits inside an airtight “body box” equipped to measure pressure and volume changes.^{14,38} Helium dilution and nitrogen washing can also be used to measure functional residual capacity in patients with COPD,¹⁴ but body plethysmography is considered to be a more accurate method of lung volume evaluation in patients with severe airflow obstruction.^{14,38} Radiographic techniques can also be used, but due to a lack of standardization, they are not typically utilized in clinical practice.¹⁴ Measurement of IC may complement other lung volume measures as part of assessment of hyperinflation.¹⁶ This can be measured using either spirometry or body plethysmography.^{39,40}

In addition to evaluating hyperinflation, ADLs, physical activity, exercise capacity, and dyspnea should all be assessed in patients with COPD in primary care. It is known that patients may self-limit ADLs to avoid symptoms of COPD; in doing so, worsening symptoms may be underappreciated,

and subsequently underreported, by the patient. Thus, it is essential that physicians ask patients with COPD, as well as individuals at risk of COPD, questions about changes in their physical activity or ability to perform common tasks. There are a number of methods to measure functional performance, but for a simple assessment of ADLs, clinicians can ask the patient or caregiver questions related to basic daily tasks.¹¹ In early COPD, patients who experience mild dyspnea during exercise should be able to perform most productive activities. Patients with stable COPD and moderate dyspnea during exercise should be able to carry out most of the higher functioning ADLs, whereas patients with severe COPD may struggle to complete basic ADLs without assistance.¹¹ It should be noted, however, that patients may experience dyspnea with fairly routine activities, and even reduce physical activity at relatively early stages of airflow limitation.^{41,42}

There is a clear distinction between symptom assessment tools that *should* be used, and which of these *can* be used practically in primary care. Although family physicians rarely perform spirometry or measure lung volumes in the clinic, it is important to highlight that spirometry assessment is conducted by some primary care practitioners, and should be utilized more readily in primary care to provide reinforcement of diagnoses. Similarly, the St. George’s Respiratory Questionnaire and the Chronic Respiratory Questionnaire, which are widely used in the scientific literature to assess symptoms,

TABLE 1 Summary of commonly used dyspnea measures in primary care^{5,44,45}

Dyspnea measure	Key features	Strengths	Limitations
COPD Assessment Test (CAT)	Evaluates 8 items on a 6-point scale, corresponding to health status impairment in COPD Higher scores represent worse health	Short, simple questionnaire Covers wide range of symptoms Well-validated and reliable Correlates closely with SGRQ Readily available	Does not categorize patients into symptom severity groups for scores in the range of 10–40
Medical Research Council (MRC) Dyspnea Scale	Evaluates everyday situations/ activity levels on a 5-point scale Higher scores represent greater disability	Short, simple questionnaire Well-validated and reliable Relates well to other measures of health status Able to predict future mortality risk Readily available	Less effective at detecting change in response after an intervention than alternative measures Considers dyspnea alone, so does not account for the broader impact of COPD
COPD Control Questionnaire (CCQ)	Evaluates 10 items on a 6-point scale based on the previous week's symptoms, measuring COPD-related health status Higher scores represent worse health	Short, simple questionnaire Well-validated and reliable Measures functional and mental capacities as well as symptoms Readily available	Does not categorize patients into symptom severity groups
Chronic Respiratory Questionnaire (CRQ)	Evaluates 20 items on a 7-point scale across 4 domains: dyspnea, fatigue, emotional function, mastery Higher scores represent better health-related quality of life	Well-validated and reliable Responds well to changes over time	License required to use questionnaire Longer than alternative dyspnea measures Does not categorize patients into symptom severity groups

Abbreviations: COPD, chronic obstructive pulmonary disease; SGRQ, St. George's Respiratory Questionnaire.


are generally considered to be too time-consuming for use in routine clinical practice⁵; the Transition Dyspnea Index is similarly lengthy.⁴³ However, shorter measures, such as the COPD Assessment Test (CAT) and the COPD Control Questionnaire are suitable,⁵ with the CAT score representing the best available tool for primary care physicians to evaluate COPD symptoms (**TABLE 1**). The International Primary Care Respiratory Group Research Subcommittee was set up to provide guidance on the best measures of quality of life in COPD.⁴⁴ The committee scored the CAT, COPD Control Questionnaire, and Chronic Respiratory Questionnaire highly for a primary care population.⁴⁴ An additional tool often useful in clinical practice is the Medical Research Council (MRC) Dyspnea Scale,⁵ but it is important to note that this measure does not provide information on any symptoms other than dyspnea.

Other tests may be useful in assessing the impact of an intervention, be it pharmacologic or nonpharmacologic, on dyspnea severity. For example, increases in the 6-minute-walk distance (6MWD) have been shown to correlate with

improvements in dyspnea.⁴⁶ The 6MWD has also been shown to be an important predictor of hospitalization and mortality in patients with COPD.⁴⁷ However, it is important to note that improvements in 6MWD show only a very weak correlation with patient-reported outcomes,⁴⁸ and may be a less sensitive measure for patients with less disability than those with more profound functional limitation.⁴⁹ Moreover, 6MWD can be affected by a patient's psychologic motivation,^{6,50} as well as other comorbidities observed in patients with COPD, such as osteoporosis, heart failure, and peripheral vascular disease.^{46,51} Although not used for COPD diagnosis or evaluation of dyspnea or physical activity limitation, a chest X-ray can also be a useful tool for excluding alternative diagnoses, as well as for detecting significant comorbidities in patients with COPD, such as concomitant respiratory, cardiac, and skeletal diseases.⁵

Management of dyspnea and hyperinflation in primary care

Physicians can utilize a variety of pharmacologic and

FIGURE 4 The crucial role of daily activity in patients with COPD³⁴

nonpharmacologic strategies to reduce hyperinflation and dyspnea and improve physical activity in patients with COPD (**FIGURE 4**).³⁴

Pulmonary rehabilitation is a tailored intervention that encompasses exercise training, education, and self-management support for people with chronic respiratory disease, based on detailed assessment of their exercise capacity and symptoms.⁵² Pulmonary rehabilitation is as important as medication in COPD management, providing a cost-effective intervention with minimal adverse effects.⁵³ Moreover, pulmonary rehabilitation has been shown to benefit patients with mild to severe dyspnea (as classified according to the Medical Research Council dyspnea scale), demonstrating the value of successful execution of these programs in patients with COPD, irrespective of disease severity.⁵⁴ Although the most significant improvements in patient quality of life are observed when a multimodality approach is used, exercise and proper pulmonary rehabilitation programs have been shown to improve quality of life more than medication alone.^{5,55} Notably, there are few supporting data for the use of supplemental oxygen in patients experiencing dyspnea without hypoxemia. Oxygen supplementation is only of minimal benefit to relieving the sensation of dyspnea.^{56,57}

The relationship between the impact of pulmonary rehabilitation in patients with COPD and frailty scores has also been evaluated. Frailty scores are calculated based on an individual's level of physical activity, and other key criteria that are indicative of their ability to self-manage their medical condition.⁵⁸ These scores are particularly relevant in the context of COPD, given the high prevalence of the condition in older

people.⁵⁸ Although frailty is a strong independent predictor of noncompletion of pulmonary rehabilitation, completion of a pulmonary rehabilitation program in patients who are frail has been shown to reverse their frailty in the short term.⁵⁸ It is therefore important that physicians guide and encourage these patients for the duration of a pulmonary rehabilitation program, from initiation through to completion, to ensure that those who are likely to derive the greatest benefit from pulmonary rehabilitation are supported to do so.

In addition to pulmonary rehabilitation, other nonpharmacologic interventions have emerged in recent years that may help to relieve dyspnea in patients with COPD. Airway clearance devices, such as acapella (Smiths Medical; Minneapolis, MN), Flutter (Allergan; Dublin, Ireland), Lung Flute (Medical Acoustics; Buffalo, NY), Quake (Thayer Medical; Tucson, AZ), and Aerobika (Monaghan Medical; Plattsburgh, NY) promote the clearance of sputum through the application of positive expiratory pressure, possibly allowing medicines to penetrate the lungs more effectively, and improving diffuse airflow obstruction.⁵⁹⁻⁶¹ Incorporating an airway clearance device into a bronchodilator therapy regimen has been shown to improve dyspnea scores, both before and after exercise, compared with bronchodilator therapy combined with a nonfunctional control device in patients with severe COPD.⁵⁹ In addition, noninvasive forms of ventilation, such as continuous positive airway pressure and bi-level positive airway pressure (BiPAP), have been shown to effectively reduce dyspnea in patients with COPD.^{62,63} In a 24-month study in patients with severe COPD, resting dyspnea improved significantly in patients using the BiPAP Auto-Trak (Philips Respironics, Best,

The Netherlands) in conjunction with their regular bronchodilator therapy, compared with those receiving long-term oxygen therapy in addition to their typical therapeutic regimen.⁶³ Further studies are required to establish the impact of these devices in the management of dyspnea and other symptoms of COPD.

These nonpharmacologic interventions can be supplemented with pharmacologic treatments to help patients achieve their treatment goals of improved dyspnea and increased exercise performance. Bronchodilators, which form the basis of various COPD treatment options, include⁵:

- short-acting muscarinic antagonists (SAMAs), such as ipratropium
- short-acting β_2 -agonists (SABAs), such as albuterol, levalbuterol, and terbutaline
- SAMA/SABA combinations
- LAMAs, such as aclidinium, glycopyrrolate, tiotropium, and umeclidinium
- long-acting β_2 -agonists (LABAs), such as arformoterol, indacaterol, formoterol, olodaterol, salmeterol, and vilanterol
- LAMA/LABA combinations (umeclidinium/vilanterol, tiotropium/olodaterol, glycopyrrolate/formoterol, glycopyrrolate/indacaterol)

Inhaled corticosteroids can also be used in a fixed-dose combination with a LABA, which can be combined with a LAMA, in select patients⁵; however, these combination products may have minimal value in treating dyspnea unless asthma is concomitantly present.^{5,64} Further discussion of the different treatment options available for patients with COPD can be found in the final article of this supplement.

In addition to improving quality of life, long-acting bronchodilators, such as LAMAs, LABAs, and LAMA/LABA combinations, increase expiratory flow, reduce dynamic hyperinflation, and improve exercise capacity of patients.⁶⁵⁻⁶⁷ As disease severity worsens, physicians may opt for long-acting bronchodilator options that have twice-daily dosing, which may confer a benefit in improving night-time symptom control.⁶⁸

As well as active pharmacologic and nonpharmacologic interventions, physicians should always encourage smoking cessation in patients with COPD, as this has the greatest capacity to influence the natural course of the disease.⁵ It is essential that health care providers continually deliver smoking cessation messages to patients with COPD; patients can also be supported to stop smoking by using nicotine replacement therapy, pharmacologic interventions, attending smoking cessation programs, and counseling.⁵

Lung volume reduction surgery may also be considered as a strategy for the management of dyspnea in severe, refrac-

tory COPD.⁶⁹ Similarly, nonsurgical bronchoscopic interventions are being developed that look to achieve similar results to lung volume reduction surgery, including endobronchial one-way valves, lung volume reduction coils, airway bypasses, adhesives, and vapor therapy.²³

CASE STUDY:

The primary care physician assessed KD's dyspnea using the CAT and ordered a chest X-ray to identify any significant comorbidities, such as concomitant respiratory, skeletal, or cardiac diseases. As KD's CAT score was 17, and her symptoms were uncontrolled on LAMA monotherapy, her physician prescribed a long-acting LAMA/LABA combination, along with pulmonary rehabilitation. The physician also counseled KD on the importance of smoking cessation, and referred her to a local smoking cessation program.

Conclusions

Dyspnea, the most common symptom of COPD and the primary consequence of the condition's characteristic lung hyperinflation, is a heavy burden on the lives of patients. The impact of dyspnea is perhaps most apparent in the context of physical activity, with activity limitation observed frequently in patients with COPD, regardless of disease stage. This can affect patients' quality of life significantly, and has long-term consequences on disease progression. Improving dyspnea and increasing exercise endurance should therefore be a key goal for COPD management, which should encompass both nonpharmacologic interventions, such as pulmonary rehabilitation, and pharmacologic interventions, such as use of bronchodilator therapy. ●

REFERENCES

1. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2006;3(2):180-184.
2. Parshall MB, Schwartzstein RM, Adams L, et al; American Thoracic Society Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. *Am J Respir Crit Care Med*. 2012;185(4):435-452.
3. Kessler R, Partridge MR, Miravittles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. *Eur Respir J*. 2011;37(2):264-272.
4. Agustí A, Hedner J, Marin J, Barbé F, Cazzola M, Rennard S. Night-time symptoms: a forgotten dimension of COPD. *Eur Respir Rev*. 2011;20(121):183-194.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2017. <http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/>. Accessed November 27, 2017.
6. O'Donnell DE, Gebke KB. Activity restriction in mild COPD: a challenging clinical problem. *Int J Chron Obstruct Pulmon Dis*. 2014;9:577-588.
7. Elbehairy AF, Ciavaglia CE, Webb KA, et al; Canadian Respiratory Research Network. Pulmonary gas exchange abnormalities in mild chronic obstructive pulmonary disease. Implications for dyspnea and exercise intolerance. *Am J Respir Crit Care Med*. 2015;191(12):1384-1394.
8. Barriga S, Rodrigues F, Bárbara C. Factors that influence physical activity in the daily life of male patients with chronic obstructive pulmonary disease. *Rev Port Pneumol*. 2014;20(3):131-137.
9. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2005;171(9):972-977.
10. Haas F, Salazar-Schicci J, Axen K. Desensitization to dyspnoea in chronic obstructive

- pulmonary disease. In: Casaburi R, Petty TL, eds. *Principles and Practice of Pulmonary Rehabilitation*. Philadelphia, PA: W.B. Saunders; 1993:241-251.
11. Belfer MH, Reardon JZ. Improving exercise tolerance and quality of life in patients with chronic obstructive pulmonary disease. *J Am Osteopath Assoc*. 2009;109(5):268-278.
 12. Troosters T, van der Molen T, Polkey M, et al. Improving physical activity in COPD: towards a new paradigm. *Respir Res*. 2013;14:115.
 13. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J*. 2004;23(6):932-946.
 14. Gagnon P, Guenette JA, Langer D, et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2014;9:187-201.
 15. Ferguson GT. Why does the lung hyperinflate? *Proc Am Thorac Soc*. 2006;3(2):176-179.
 16. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2001;164(5):770-777.
 17. Dubé BP, Guerdier A, Morelot-Panzini C, Laveneziana P. The clinical relevance of the emphysema-hyperinflated phenotype in COPD. *COPD Res Pract*. 2016;2:1.
 18. Scano G, Stendardi L, Grazzini M. Understanding dyspnoea by its language. *Eur Respir J*. 2005;25(2):380-385.
 19. Chwienyczek S, Javadzadeh S, Booth S, Farquhar M. Association of descriptors of breathlessness with diagnosis and self-reported severity of breathlessness in patients with advanced chronic obstructive pulmonary disease or cancer. *J Pain Symptom Manage*. 2016;52(2):259-264.
 20. Thomas M, Decramer M, O'Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. *Prim Care Respir J*. 2013;22(1):101-111.
 21. Gosselink R. Controlled breathing and dyspnea in patients with chronic obstructive pulmonary disease (COPD). *J Rehabil Res Dev*. 2003;40(5 Suppl 2):25-33.
 22. O'Donnell DE, Webb KA, Neder JA. Lung hyperinflation in COPD: applying physiology to clinical practice. *COPD Res Pract*. 2015;1:4.
 23. Browning RE, Parrish S, Sarkar S, et al. Bronchoscopic interventions for severe COPD. *J Thorac Dis*. 2014;6(Suppl 4):S407-S415.
 24. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. *Chest*. 2002;121(5):1434-1440.
 25. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. *Br Med J*. 1959;2(5147):257-266.
 26. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 1999;160(2):542-549.
 27. Light RW. Mechanics of respiration. In: George RB, ed. *Chest Medicine: Essentials of Pulmonary and Critical Care Medicine*. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:24-38.
 28. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2005;171(6):591-597.
 29. O'Donnell DE, Guenette JA, Maltais F, Webb KA. Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. *Chest*. 2012;141(3):753-762.
 30. O'Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. *COPD*. 2007;4(3):225-236.
 31. Holland AE. Physiotherapy management of acute exacerbations of chronic obstructive pulmonary disease. *J Physiother*. 2014;60(4):181-188.
 32. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. *N Engl J Med*. 2010;362(3):217-227.
 33. Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. *Am J Respir Crit Care Med*. 2009;180(6):506-512.
 34. Di Marco F, Santus P, Sotgiu G, Blasi F, Centanni S. Does improving exercise capacity and daily activity represent the holistic perspective of a new COPD approach? *COPD*. 2015;12(5):575-581.
 35. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. *Chest*. 2002;121(4):1042-1050.
 36. Bailey KL. The importance of the assessment of pulmonary function in COPD. *Med Clin North Am*. 2012;96(4):745-752.
 37. Burkhardt R, Pankow W. The diagnosis of chronic obstructive pulmonary disease. *Dtsch Arztebl Int*. 2014;111(49):834-845, quiz 846.
 38. O'Donnell CR, Bankier AA, Stiebelhner L, Reilly JJ, Brown R, Loring SH. Comparison of plethysmographic and helium dilution lung volumes: which is best for COPD? *Chest*. 2010;137(5):1108-1115.
 39. Crieé CP, Soricter S, Smith HJ, et al; Working Group for Body Plethysmography of the German Society for Pneumology and Respiratory Care. Body plethysmography—its principles and clinical use. *Respir Med*. 2011;105(7):959-971.
 40. Lutfi MF. The physiological basis and clinical significance of lung volume measurements. *Multidiscip Respir Med*. 2017;12:3.
 41. Lahaije AJ, van Helvoort HA, Dekhuijzen PN, Vercoulen JH, Heijdra YF. Resting and ADL-induced dynamic hyperinflation explain physical inactivity in COPD better than FEV1. *Respir Med*. 2013;107(6):834-840.
 42. Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. *Respir Med*. 2010;104(7):1005-1011.
 43. Calverley PMA, Georgopoulos D. Symptoms and signs of COPD. In: Siafakas NM, ed. *Management of Chronic Obstructive Pulmonary Disease: European Respiratory Society Journals*; 2006.
 44. Cave AJ, Atkinson L, Tsiligianni IG, Kaplan AG. Assessment of COPD wellness tools for use in primary care: an IPCRG initiative. *Int J Chron Obstruct Pulmon Dis*. 2012;7:447-456.
 45. Cazzola M, Hanania NA, MacNee W, Rüdell K, Hackford C, Tamimi N. A review of the most common patient-reported outcomes in COPD—revisiting current knowledge and estimating future challenges. *Int J Chron Obstruct Pulmon Dis*. 2015;10:725-738.
 46. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166(1):111-117.
 47. Polkey MI, Spruit MA, Edwards LD, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. *Am J Respir Crit Care Med*. 2013;187(4):382-386.
 48. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schünemann HJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. *Eur Respir J*. 2008;32(3):637-643.
 49. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. *Arch Phys Med Rehabil*. 2010;91(2):221-225.
 50. Grant A, Moore L. Pulmonary rehabilitation. In: Blackler L, Jones C, Mooney C, eds. *Managing Chronic Obstructive Pulmonary Disease*. West Sussex, England: John Wiley & Sons; 2007.
 51. Crisafulli E, Gorgone P, Vagaggini B, et al. Efficacy of standard rehabilitation in COPD outpatients with comorbidities. *Eur Respir J*. 2010;36(5):1042-1048.
 52. Spruit MA, Singh SJ, Garvey C, et al; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med*. 2013;188(8):e13-e64.
 53. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. *Chest*. 2007;131(5 Suppl):4S-42S.
 54. Evans RA, Singh SJ, Collier R, Williams JE, Morgan MD. Pulmonary rehabilitation is successful for COPD irrespective of MRC dyspnoea grade. *Respir Med*. 2009;103(7):1070-1075.
 55. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2015;(2):CD003793.
 56. Stoller JK, Panos RJ, Krachman S, Doherty DE, Make B; Long-term Oxygen Treatment Trial Research Group. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. *Chest*. 2010;138(1):179-187.
 57. Ekström M, Ahmadi Z, Bornefalk-Hermansson A, Abernethy A, Currow D. Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. *Cochrane Database Syst Rev*. 2016;11:CD006429.
 58. Maddocks M, Kon SS, Canavan JL, et al. Physical frailty and pulmonary rehabilitation in COPD: a prospective cohort study. *Thorax*. 2016;71(11):988-995.
 59. Wolkove N, Kamel H, Rotaple M, Baltzan MA Jr. Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD. *Chest*. 2002;121(3):702-707.
 60. Chatburn RL. High-frequency assisted airway clearance. *Respir Care*. 2007;52(9):1224-1235; discussion 1235-1227.
 61. Clini E. Positive expiratory pressure techniques in respiratory patients: old evidence and new insights. *Breathe*. 2009;6(2):153-159.
 62. Petrof BJ, Legaré M, Goldberg P, Milic-Emili J, Gottfried SB. Continuous positive airway pressure reduces work of breathing and dyspnea during weaning from mechanical ventilation in severe chronic obstructive pulmonary disease. *Am Rev Respir Dis*. 1990;141(2):281-289.
 63. Clini E, Sturani C, Rossi A, et al; Rehabilitation and Chronic Care Study Group; Italian Association of Hospital Pulmonologists (AIP). The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. *Eur Respir J*. 2002;20(3):529-538.
 64. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. *Thorax*. 1998;53(6):477-482.
 65. Berton DC, Reis M, Siqueira AC, et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. *Respir Med*. 2010;104(9):1288-1296.
 66. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. *Eur Respir J*. 2004;23(6):832-840.
 67. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. *Chest*. 2006;130(3):647-656.
 68. Blasi F, Canonica GW, Miravittles M. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients [published correction appears in *Respir Res*. 2017;18(1):35]. *Respir Res*. 2017;18(1):19.
 69. Shah AA, D'Amico TA. Lung volume reduction surgery for the management of refractory dyspnea in chronic obstructive pulmonary disease. *Curr Opin Support Palliat Care*. 2009;3(2):107-111.